Introduction
Diabetes mellitus affects over 463 million adults worldwide, according to the International Diabetes Federation, primarily due to persistently high blood sugar levels, or hyperglycemia. Effective therapy for high blood sugar is crucial to prevent complications such as cardiovascular disease, neuropathy, retinopathy, and kidney failure. This article explores evidence-based strategies for managing hyperglycemia in diabetes, emphasizing a multifaceted approach that combines lifestyle changes, medications, and monitoring.
Causes and Symptoms of High Blood Sugar
Hyperglycemia occurs when the body either fails to produce sufficient insulin (Type 1 diabetes) or becomes resistant to it (Type 2 diabetes). In Type 1, an autoimmune attack destroys pancreatic beta cells, halting insulin production. Type 2, comprising 90-95% of cases, involves insulin resistance exacerbated by obesity, sedentary lifestyle, and genetics. Blood glucose levels exceeding 180 mg/dL post-meal or 130 mg/dL fasting define hyperglycemia per American Diabetes Association (ADA) guidelines.
Common symptoms include polyuria (excessive urination), polydipsia (thirst), unexplained weight loss, fatigue, and blurred vision. Chronic elevation leads to diabetic ketoacidosis (DKA) in Type 1 or hyperosmolar hyperglycemic state (HHS) in Type 2, both medical emergencies with mortality rates up to 20-30% if untreated. Early recognition transitions seamlessly into therapeutic interventions.
Lifestyle Modifications
Cornerstone therapy begins with lifestyle adjustments. Dietary changes focus on low-glycemic index foods, reducing refined carbohydrates, and emphasizing fiber-rich vegetables, lean proteins, and healthy fats. The Mediterranean diet has shown to lower HbA1c by 0.3-2% in trials. Portion control via plate methods—half non-starchy veggies, quarter protein, quarter whole grains—helps maintain euglycemia.
Exercise is equally vital; 150 minutes weekly of moderate aerobic activity, like brisk walking, improves insulin sensitivity by 30-50%. Resistance training twice weekly builds muscle, enhancing glucose uptake. Weight loss of 5-10% in overweight individuals can normalize blood sugar in prediabetes or early Type 2, bridging the gap to pharmacological support.
Pharmacological Therapies
For inadequate lifestyle control, medications target various pathways. First-line for Type 2 is metformin, reducing hepatic glucose production and improving sensitivity, with cardiovascular benefits per UKPDS trial. Sulfonylureas stimulate insulin release, while GLP-1 receptor agonists (e.g., semaglutide) mimic incretins, promoting weight loss and lowering HbA1c by 1-2%.
SGLT2 inhibitors (e.g., empagliflozin) promote urinary glucose excretion, reducing heart failure risk by 35% as in EMPA-REG OUTCOME. Type 1 and advanced Type 2 require insulin: basal (long-acting like glargine) for steady control, bolus (rapid-acting like aspart) for meals. Continuous subcutaneous insulin infusion via pumps offers precise delivery.
Monitoring and Emerging Treatments
Self-monitoring of blood glucose (SMBG) or continuous glucose monitoring (CGM) systems like Dexcom track trends, aiming for 70-180 mg/dL targets. HbA1c below 7% reflects 3-month average control. Innovations include hybrid closed-loop systems automating insulin delivery and stem cell therapies regenerating beta cells in trials.
Conclusion
Managing high blood sugar in diabetes demands personalized, comprehensive therapy integrating lifestyle, pharmacotherapy, and technology. Adherence reduces microvascular complications by 25% per DCCT/UKPDS data. Patients should consult endocrinologists for tailored plans, ensuring long-term health and quality of life through vigilant, proactive management.